PMP is a very rare disease occurring in 2 of 10,000
laparotomies.2,3 It is mostly prevalent in women aged
between 50 and 70.
In large majority of cases (80%), PMP arises from appendicular
disease and not ovarian disease although ovarian seeding,
observed in nearly 90% of the female patients may be misleading.3
Christine Szych et al have reported that mucinous tumours
involving the appendix and ovaries in women with PMP are
clonal and derived from a single site, most likely the
appendix, based on the analysis of k-ras mutations and
allelic losses of chromosomes of 18q, 17p, 5q and 6q in
a substantial number of morphologically uniform cases
of PMP.4
PMP arising from colon, breast, endometrium, pancreas,
common bile duct carcinoma and urachus have also been
reported.
Its biology is characterized by a redistribution phenomenon
with large amount of extra cellular mucin. The mucin producing
cells in PMP are poorly adherent and circulate with peritoneal
fluid. They are easily dislodged from the surface of the
bowel by constant peristalsis. They only seed at sites
of relative stasis. This process has been termed the ‘redistribution
phenomenon’.6
It is characterized by the presence in the peritoneal
cavity of three elements-mucinous neoplastic cells, mucinous
ascites and diffuse mucinous implants.7
It can be classified into three histologic groups: disseminated
peritoneal adenomucinosis (DPAM)- the one present in our
case, peritoneal mucinous carcinomatosis (PMCA) and intermediate
group.8,9
O’Connell JT et al have reported that PMP is a
disease of MUC 2- expressing goblet cells. MUC 2- expression
accounts for voluminous deposits of extra cellular mucin
(mucin: cell ratios exceeding 10:1). Because mucinous
tumours of the appendix similarly express MUC 2, MUC 2
expression profile also supports an appendiceal rather
than ovarian origin for PMP.
The common presentation of PMP is pain in abdomen, distension
of abdomen and/or lump in abdomen. Fever, anorexia, nausea,
vomiting and weight loss may be associated. Thus the clinical
features are vague and in our country could be mistaken
for abdominal tuberculosis.5
The common sites of tumour load are the greater omentum
(omental cake), the undersurface of the right hemidiaphragm,
the right retrohepatic space, the left abdominal gutter,
at the ligament of Treitz and pelvic spaces. Peritoneal
surfaces of bowel are spared. The tumour progresses by
the production of mucus, exfoliation of tumour cells and
redistribution of these cells around abdomen.5
Despite the presence of distended abdomen with nonshifting
ascites on physical examination, diagnosis is seldom absolute
until laparotomy is performed. Laboratory tests are of
little help but fortunately over the past few years, radiological
imaging techniques are proving to be extremely useful
in reaching diagnosis of PMP.
The pertinent cytological features of PMP include a mucinous
background with mesothelial cells and histiocytes. The
well-differentiated columnar epithelial cells producing
mucin usually display minimal nuclear features of malignancy.
Plain abdominal X-rays taken during the later stages
of the disease show central displacement of bowels with
obliteration of the psoas muscle border. When used in
conjunction with barium studies, the proximal extent of
the disease can be assessed and a possible extrinsic tumour
causing large bowel obstruction can be ruled out.
USG shows septated ascites with numerous suspended echoes
that do not move as the patient changes position (these
were seen in our case) and scalloping of the liver.5,13
CT scan shows four basic patterns-scalloping of intra
abdominal organs due to extrinsic pressure of adjacent
peritoneal implants (diagnostic signs that distinguishes
mucinous from fluid ascites on CT and which was seen in
our case), diffuse peritoneal infiltration appearing similar
to ascites with separated fluid pockets filling the peritoneal
cavity, posterior displacement of the intestines with
numerous low density masses and calcifications and intrahepatic
low density attenuated lesions. PMP is not characterized
by haematogenous or lymphatic metastases, so the presence
of lymphadenopathy should bring the diagnosis of PMP into
question.6,13 But in our case CT showed bilateral diaphragmatic
lymph nodes, which were probably concurrently involved.
Finally, MRI, which is still being investigated, may
prove more helpful than CT especially in assessing the
rare visceral invasion by mucinous tumours. One major
disadvantage is the poor cost effectiveness compared with
CT.13
In summary, preoperative diagnosis could therefore be
made with careful physical examination in conjunction
with USG and CT. However, explorative laparotomy still
remains the main diagnostic tool of choice. A positive
finding is indicated by the presence of litres of yellowish
grey mucoid material involving both the omental and peritoneal
surfaces.
The goal of therapy should be a multimodal concept combining
complete cytoreduction (defined as tumour nodules less
than 2.5 mm in diameter remaining after surgery) with
the use of peritonectomy procedures and peri and postoperative
intraperitoneal chemotherapy. Aggressive and “repetitive
debulking” surgery including appendicectomy, bilateral
oophorectomy and omentectomy at the initial procedure
should be undertaken. Surgical peritonectomy aims to achieve
the complete removal of tumour cells at the macroscopic
level.5,10,11
Subsequently intraoperatively or in the immediate postoperative
phase when the absence of adhesions allows for a homogeneous
intra abdominal spread of cytotoxic drugs, heated intraperitoneal
chemotherapy with 5 - fluorouracil (5FU) and mitomycin
C (MMC) represents the most solidly established treatment
designed to treat residual microscopic disease. Hyperthermia
enhances the penetration of cytostatic drugs into tumour
tissue and also shows synergism with various cytostatic
drugs. As the penetration depth of drugs into tissue is
limited, therefore intraperitoneal chemotherapy can only
be effective in patients with minimal disease after aggressive
surgery.10,11
Intra peritoneal chemotherapy may cause systemic toxicity,
dependant on the drug used. Systemic chemotherapy is rarely
indicated. Abdominal CT is an excellent technique to follow
up these patients for recurrence.5 Radiotherapy of the
abdomen with pelvic boost can be given in cases unresponsive
to chemotherapy.
The clinical features, which correlate significantly
with therapy failure, are tumour site, histopathological
grade, preoperative cancer volume and completeness of
cancer removal by cytoreductive surgery. Advancing abdominal
disease caused by intestinal obstruction account for the
majority of patients' morbidity and mortality.
Tumour markers are also useful for diagnosis and follow
up. The measurement of the tumour marker Carbohydrate
Antigen 19.9 (CA 19.9) is useful in evaluating therapy
in patients with PMP treated with cytoreductive surgery
and heated intraperitoneal chemotherapy. It is a prognostic
factor for predicting recurrent disease.12
In 1996, Kairemo KJ et al stated that immunohisto chemistry
based on digital quantitative autoradiography utilizing
radio labelled monoclonal antibody B 72.3 (Mo Ab) recognizing
TAG - 72 antigen on pseudomyxoma tumours, can be used
for earlier diagnosis and more accurate location of residual
disease after operations and evaluating treatment response.14 |